Experience of Surgical Resection for Hilar Cholangiocarcinomas at a Japanese Single Cancer Institute by Nanashima Atsushi et al.
Nanashima et al., Page 1 of 19 
Original Paper 
Experience of Surgical Resection for  
Hilar Cholangiocarcinomas at a Japanese Single Cancer Institute  
Atsushi Nanashima1, Syuuichi Tobinaga1, Takafumi Abo1,  Ryusuke Machino1,  
Hiroaki Takeshita1, Takashi Nonaka1, Shigekazu Hidaka1, Kenji Tanaka1,  
Masaki Kunizaki1, Terumitsu Sawai1, Toru Yasutake1,Takeshi Nagayasu1 
 
1Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki 
University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 
852-8501, Japan 
 
Running title: Hepatectomy in hilar cholangiocarcinoma 
 
Corresponding and reprint requests to: Atsushi Nanashima, M.D. 
Division of Surgical Oncology, Department of Translational Medical Sciences, 
Nagasaki University Graduate School of Biomedical Sciences, 
1-7-1 Sakamoto, Nagasaki 852-8501, JAPAN 
Tel.: +81-95-819-7304 , Fax: +81-95-819-7306 
E-mail: a-nanasm@nagasaki-u.ac.jp 
Nanashima et al., Page 2 of 19 
ABSTRACT 
Background/Aims: Surgical resection is a radical treatment option for hilar bile duct 
carcinoma (HBDC); however, it is still difficult to cure and postoperative morbidity is 
high at this stage.  
Methodology: We examined the demographics, surgical records and outcome in 38 
patients with hilar cholangiocarcinoma undergoing operation.  
Results: Five patients (13%) underwent probe laparotomy because of peritoneal 
dissemination or liver metastasis. Of 33 patients, extended hemi-hepatectomy was 
performed in 32 patients. Postoperative complications were observed in 46% including 
hepatic failure in 3, and hospital death was observed in 4 patients. Advanced tumor stage 
more than stage III was observed in 23 patients. Curability of operation was A in 5 
patients, B in 17, and C in 11 and postoperative adjuvant chemotherapy was administered 
in 24% including photodynamic therapy in 3. Tumor recurrence was observed in 41% of 
HBDC patients. The 3- and 5-year tumor-free survival was 38% and 10%, respectively 
and 3- and 5-year overall survival was 48% and 32%, respectively. By comparison with 
tumor stage or final curability, survival rates were not significantly different between 
groups.  
Conclusions: Surgical resection is still the only curative treatment option to improve 
patient survival even in advanced stage HBDC. 
KEYWORDS: hepatectomy, pancreatoduodenectomy, hilar bile duct carcinoma radical 
resection 
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ABBREVIATIONS: Hilar bile duct carcinomas (HBDC), 
hepatopancreatoduodenectomy (HPD), percutaneous transhepatic biliary drainage 
(PTBD), preoperatively portal vein embolization (PVE), percutaneous biliary drainage 
tube (PTBD), endoscopic retrograde biliary drainage tube (ERBD), 
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INTRODUCTION 
Surgical resection is the only curable treatment for hilar bile duct carcinomas (HBDC), 
and concurrent extended hepatectomy or hepatopancreatoduodenectomy (HPD) is 
necessary to accomplish complete (R0) resections, which may be associated with good 
patient prognosis (1-4). The resectability of hepatobiliary malignancies has markedly 
improved with the improvement of operative techniques and the introduction of 
preoperatively portal vein embolization (PVE) (5, 6). However, physical stress in patients 
is relatively severe and postoperative morbidity and mortality rates are still not low (1. 3, 
6-8). Therefore, the indication of operation for HBDC should be carefully decided. In the 
present report, we examined our series of HBDC in 38 patients at a Japanese single cancer 




We analyzed 38 patients with HBDC who underwent operation in the Division of 
Surgical Oncology, Department of Translational Medical Sciences, Nagasaki University 
Graduate School of Biomedical Sciences (NUGSBS) between 1997 and 2008. The study 
design was approved by the Human Ethics Review Board of our institution.  Informed 
consent for data collection was obtained by each patient during this period. Anesthetic 
and patient data were retrieved in the NUGSBS database. Tumor stage and curability was 
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followed by the Classification of Biliary Tract Carcinoma by the Japanese Society of 
Biliary Surgery (9). 
 
Operative indications, procedures and follow-up 
Extended hepatectomy is a basic surgical option for HBDC with Bismuth type III 
and IV. Hepatopancreaticoduodenectomy (HPD) is necessary in cases where HBDC is 
widely extended to the bile duct in the pancreatic head. Even in cases with remarkable 
metastatic lymph node at para-aortic lesion, complete (=radical) resection with extended 
lymphadenectomy was performed. In cases with liver metastasis, peritoneal 
dissemination, or more distant metastasis, radical operation was avoided. In cases with 
good general conditions and liver function, radical operation was carried out but the 
border of patient age was not decided. Right or left hemi-hepatectomy was a basic option, 
which included resection of the total caudate lobe and extra-hepatic bile duct. 
Extension of carcinoma along the bile duct was preoperatively diagnosed by precise 
cholangiography via percutaneous biliary drainage tube (PTBD) or endoscopic 
retrograde biliary drainage tube (ERBD), contrast multi-detector row computed 
tomography, and magnetic resonance cholangiography. In liver resection, the volume to 
be resected was estimated preoperatively based on the results of indocyanine green 
retention rate at 15 minutes using Takasaki’s formula (10).  The liver volume, excluding 
tumor volume (cm3), was measured by CT volumetry (11).  We routinely clamped the 
hepatoduodenal ligament to occlude total inflow to the liver during transection.  We also 
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routinely used the forceps fracture method (12) and an ultrasonic dissector (USU 
MH-207, Olympus, Tokyo, Japan) for the transection of liver parenchyma.  Since 2004, 
we have determined liver function by 99m-techniteium galactosyl serum albumin (GSA) 
liver scintigraphy and functional liver volume by single photon emission computed 
tomography (SPECT)-CT fusion image (13). In patients needing pancreatic resection, 
pancreatoduodenectomy (PD) was usually performed in case of HPD. Pancreatic 
functions were not considered as operative indications. 
After discharge from hospital, the patient status, laboratory data, and disease 
recurrence were carefully checked every 3 months. Minimum follow-up period after 
operation was 12 months. 
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RESULTS 
        Patients included 6 men and 5 women with a mean age of 67.5 ± 8.0 years (± SD, 
range, 44-83 years). Male-female ratio was 23 vs. 15. Preoperative PVE was performed in 
9 patients (24%) for right hepatectomy or right trisectionectomy.  
Five patients (13%) underwent probe laparotomy due to peritoneal dissemination in 4 
patients and liver metastasis in 1. The remaining 33 patients underwent left hepatectomy 
in 15 patients, right hepatectomy in 6, right HPD in 3, left HPD in 3, right 
trisectionectomy in 3, left trisectionectomy in 2 and resection of segment 4a and segment 
5 in 1. Postoperative complications were observed in 18 patients (46%) including bile 
leak at hepaticojejunostomy in 5, hepatic failure in 3, wound infection in 3, long-term 
hyper-bilirubinemia in 2, long-term ascites in 2, pancreatic fistula at 
pancreaticojejunostomy in 1, hepatic arterial thrombosis in 1, and severe pneumonia in 1. 
Hospital death was observed in 4 patients (12%) due to hepatic failure in 3 and hepatic 
arterial thrombosis in 1.  
Final tumor stage was I in 1, II in 9, III in 8, IVa in 11 and IVb in 4. Final curability of 
operation was A in 5 patients, B in 17, and C in 11 (due to positive cancer margin at 
proximal (hepatic) cut end in 5 patients, at distal (bile duct) cut end in 2, and at dissected 
periductal structures in 4. Postoperative adjuvant chemotherapy was performed in 8 
patients (24%) including photodynamic therapy at proximal (hepatic) cut end in 3 
patients.  
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       Except patients with hospital death, in 12 of 29 patients (41%), tumor recurrence was 
observed, which included peritonitis carcinomatosa in 5 patients, liver metastasis in 4, 
local recurrence in 4, and para-aortic lymph node metastasis in 1. Eighteen patients died 
after operation, which included cancer-related death in 11 (33%), other disease in 2, and 
portal thrombosis at 3 months in 1.  
      Figures 1 and 2 show the tumor-free and overall survival after operation in 29 patients 
without hospital death. Mean tumor-free survival was 29 months, and 3- and 5-year 
survival was 38% and 10%, respectively. By comparison with tumor stage, 3-year 
tumor-free survivals were not significantly different between stages (100% in I, 27% in II, 
33% in III, 44% in IVa and b, p=0.64). By comparison with final curability, 3-year 
tumor-free survivals were not significantly different between groups either (50% in A, 
35% in B, 66% in C, p=0.38). Mean tumor-related overall survival was 40 months, and 3- 
and 5-year survival was 48% and 32%, respectively. By comparison with tumor stage, 
3-year tumor-related overall survival was not significantly different between stages 
(100% in I, 49% in II, 53% in III, 38% in IVa and b, p=0.85). By comparison with final 
curability, 3-year tumor-related overall survival was not significantly different between 
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DISCUSSION 
Nowadays, aggressive surgical exploration for HBDC combined with hepatic 
resection, resection of total caudate lobe, and extrahepatic bile duct is usually performed 
(1-4). As the techniques and perioperative management have remarkably improved, we 
have actively performed major hepatic resections for complete tumor resections (R0) 
during the last 15 years. Based on previous reports, the usefulness of R0 resection for 
HBDC has been reported since the 1990s (1-4, 14-16).  
In our series, the mean age of HBDC patients was similar to that in other reports (1,4, 
17) and, as a modern trend, many patients were older than 70 years. Other reports showed 
that patients over 80 years can undergo this major surgery if the patient has no serious 
complications and a strong performance status (18, 19). Our series included an 
83-year-old patient, and she had a good operative course. Preoperative PVE for a large 
volume of hepatectomy such as right hepatectomy or trisectionectomy has been widely 
applied, particularly in Japanese institutes at this stage (5, 6, 20, 21). By introduction of 
PVE, hepatic failure after major hepatectomy in HBDC patients significantly decreased,  
and our previous results also showed a good prognosis in patients who underwent right 
hepatectomy after PVE (22). A study of functional liver reserve in such patients showed 
the theoretical usefulness of preoperative PVE (23, 24).  
Although resectability of HBDC has been improved, advanced carcinomas were still 
found at laparotomy (2,4,7), and 13% of HBDC patients were inoperable, despite the 
detailed preoperative image examinations in our series. PTBD might be one of the causes 
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of peritoneal dissemination and, therefore, ERBD is preferable for biliary drainage before 
surgery (25). In Western countries, preoperative biliary drainage jeopardized operative 
safety (26); however, non-drained liver showed remarkable deterioration of functional 
liver reserve (27). Therefore, the safety of hepatectomy must be examined, as well as 
patient safety. At this stage, extended hemihepatectomy might be predominantly 
performed because perioperative management has been improved and operative safety 
has been accomplished (7, 15, 16). In our series, most cases underwent major 
hepatectomy and limited hepatectomy was performed in only one case. Postoperative 
complications, particularly liver failure and mortality rate, occurred frequently in our 
series. Particularly in cases with vascular anastomosis of the hepatic artery, the operative 
indication must be carefully considered preoperatively. Although severe complications 
were considerable in cases of arterial infiltration, radical operation might be valuable (3). 
We attempted to evaluate functional liver volume by 99m-Tc galactosyl serum albumin 
liver scintigraphy (23, 27). More reliable evaluation of liver function and improvement of 
surgical technique or devices would be necessary to reduce postoperative complication 
rates. Cases with widely intramural extensions of bile duct carcinoma between the 
intra-hepatic bile duct and intra-pancreatic bile duct can be completely resected by HPD 
(7).  Although HPD is still a high-level operation, HPD was performed to accomplish 
curative operation. At this stage, eventually, longer prognosis would be expected in bile 
duct carcinomas with wide extension by complete and aggressive resection. 
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By histological examinations, advanced tumors such as final stage III and IV were 
dominant in our series, as well as other reports (4,5,7,8,15,16). According to this result, 
radical operation as curability A was not common. In cases with remnant cancer cells at 
the surgical cut end, additional local treatment is necessary to avoid tumor relapse. In 3 
patients with positive cancer margin at hepatic cut end, photodynamic therapy, which is a 
cancer-specific treatment (28), was performed after the operation and local tumor 
recurrence has not been observed in these patients. Recently, anti-cancer chemotherapy 
has been effective for unresectable HBDC (29, 30) and effectiveness of adjuvant 
chemotherapy can be expected. In our series, TS-1 (Taiho Pharmaceutical Company, 
Tokyo, Japan), a novel oral fluoropyrimidine anticancer drug for gastric carcinomas (31), 
was used in stage IVa HBDC patients who had no tumor recurrence for 2 years, and the 
long-term administration was well tolerated. At this stage, tumor relapse was frequent 
despite aggressive resections in our series. Further long-term follow-up with adjuvant 
chemotherapy is necessary and development of effective anti-cancer drugs will be 
expected to improve patient survival.  
In the present study, survival rate after hepatectomy was not satisfactory compared 
to the 50% survival rates in other reports (2, 32). Tumor stage and curability were not 
associated with patient survival in the preset study. In advanced stage HBDC, 40% of  
patients achieved a 3-year survival. Therefore, even in cases of stage IVa and b, surgical 
resection would be promising and only a radical treatment option. 
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 In conclusion, major surgical resection by major hepatectomy with caudate 
resection and extra-hepatic bile duct was performed in 33 patients with hilar bile duct 
carcinomas at a single cancer center over the past 15 years. Radical operation could be 
safely performed in many cases but 4 patients had hospital stay death at this stage. 
Although advanced stage HBDC and operations of low curability were not few, a 
relatively good prognosis could be obtained after surgery. Therefore, the indication of 
hepatectomy or hepatopancreaticoduodenectomy should be considered for widely 
extensive bile duct cancer for radical treatment. Surgical resection has been still only a 
curative option and newly effective adjuvant chemotherapy will be expected to improve 
patient survival.  
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Figure legend 
Figures 1.  The tumor-free survival in patients with hilar cholangiocarcinoma who 
underwent hepatectomy.  
 
Figure 2. Overall survival in patients with hilar cholangiocarcinoma who underwent 
hepatectomy. 
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